Bicycle Therapeutics (NASDAQ:BCYC) Stock Crosses Above 50 Day Moving Average - What's Next?

Key Points

• Bicycle Therapeutics shares rose 2.6% and crossed above their 50-day moving average, trading near $3.88 versus the $3.85 average. The stock remains below its 200-day moving average of $4.61.
• Analyst sentiment is mixed, with a consensus rating of Hold and an average price target of $13.86. Ratings range from Buy to Strong Sell, including a recent price-target cut by Needham to $14.
• The company reported weaker-than-expected quarterly results, including a loss of $0.72 per share versus estimates of $0.58 and revenue of $0.63 million versus $4.22 million expected. Bicycle Therapeutics has negative profitability metrics, while institutional investors own 86.15% of the stock.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $3.85 and traded as high as $3.89. Bicycle Therapeutics shares last traded at $3.88, with a volume of 436,242 shares trading hands.

Analyst Ratings Changes

Several analysts have commented on BCYC shares. Wall Street Zen upgraded shares of Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th. Needham & Company LLC cut their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Zacks Research lowered Bicycle Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday, October 14th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of "Hold" and an average target price of $13.86.

Bicycle Therapeutics Trading Up 2.6%

The firm has a market capitalization of $271.56 million, a PE ratio of -1.42 and a beta of 1.68. The business's 50 day simple moving average is $3.85 and its 200 day simple moving average is $4.61.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.14). Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. The business had revenue of $0.63 million during the quarter, compared to the consensus estimate of $4.22 million. Analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -2.26 earnings per share for the current year.

Institutional Investors Weigh In On Bicycle Therapeutics

Several institutional investors have recently modified their holdings of BCYC. Vontobel Holding Ltd. lifted its position in Bicycle Therapeutics by 15.0% in the third quarter. Vontobel Holding Ltd. now owns 23,000 shares of the company's stock worth $85,000 after buying an additional 3,000 shares during the last quarter. Portland Investment Counsel Inc. purchased a new position in Bicycle Therapeutics during the second quarter worth $64,000. Marquette Asset Management LLC purchased a new position in Bicycle Therapeutics during the second quarter worth $309,000. FNY Investment Advisers LLC increased its position in Bicycle Therapeutics by 247.4% during the second quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company's stock valued at $111,000 after acquiring an additional 18,693 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Bicycle Therapeutics by 512.9% during the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company's stock valued at $33,000 after acquiring an additional 6,447 shares during the last quarter. 86.15% of the stock is owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics' research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.